Hexarelin’s reputation online runs on before-and-after photos and forum claims of weeks-long muscle gains, but the only “before and after” that has been measured in the human literature is a single hormone curve that rises and falls within about four hours. That gap between the marketing story and the pharmacology is the real story here. Hexarelin is one of the most potent synthetic growth hormone secretagogues ever tested in people, and also one of the least tested for anything beyond a single dose.
What twelve volunteers in 1994 showed
Two research groups working with the peptide’s originator, Deghenghi, ran the studies that still anchor almost everything known about Hexarelin in humans, and both did it the same year. Imbimbo and colleagues gave twelve healthy male volunteers single intravenous boluses of 0.5, 1 and 2 micrograms per kilogram, in a placebo-controlled, rising-dose design.[1] Growth hormone rose with the dose, peaked at about 30 minutes, and returned to baseline within four hours, with a half-life of roughly 55 minutes.[1]
55 peak growth hormone, ng/mL, after the highest tested Hexarelin dose PMID 7957536
Ghigo and colleagues, also with Deghenghi as a co-author, tested the same peptide across four routes: intravenous, subcutaneous, intranasal and oral, against a reference dose of growth-hormone-releasing hormone (GHRH).[2] A 1 microgram-per-kilogram intravenous dose of Hexarelin produced roughly twice the growth hormone response, by area under the curve, of an equal dose of GHRH.[2]
2x the growth hormone response of a matched intravenous dose of GHRH, in a head-to-head human comparison PMID 8126144
Subcutaneous dosing worked almost as well as intravenous. Intranasal and oral dosing worked too, but barely, because so little of the peptide reaches circulation intact once it leaves a vein.
Hexarelin bioavailability by route, relative to IV
Subcutaneous: 77
Intranasal: 4.8
Oral: 0.3
From a single 1994 human dose-comparison study.
That chart is the entire foundation of what “Hexarelin works” means in a lab: a same-day pharmacology study in a dozen men, run by the people who invented the molecule. Neither 1994 paper dosed anyone for more than a single day.
The before-and-after nobody has run as a trial
Ask around on forums and someone will tell you the growth hormone response fades if you dose Hexarelin every day, sometimes within a week. That claim is plausible. G-protein-coupled receptors, the class Hexarelin’s receptor belongs to, are well known to lose responsiveness after repeated agonist exposure, through mechanisms such as receptor downregulation and internalization.[3] That citation is a general review of GPCR biology. It says nothing about which specific mechanism, if any, applies to Hexarelin’s own receptor.[3]
Searching the published record for a controlled human study that dosed Hexarelin daily for a week or more and re-measured the growth hormone response turns up nothing. No such trial exists in what this search could locate. No published, controlled human trial has:
Dosed Hexarelin daily for more than one day and re-checked the growth hormone response.
Tracked repeated Hexarelin dosing in children with suspected growth hormone deficiency.
Tested the receptor mechanism behind any repeat-dose decline, in Hexarelin specifically.
What’s missing: No published, controlled human trial has dosed Hexarelin daily for more than a single day and measured whether the growth hormone response holds up. The “it stops working” claim is plausible pharmacology. Nobody has measured it in Hexarelin specifically.
The pattern would not be unusual if it turns out to be true. Opioid receptors, also G-protein-coupled, are the textbook case of a receptor that answers less and less to the same dose over repeated exposure. If Hexarelin’s receptor behaves the same way, and there is no obvious reason it would not, the interesting number is not whether tolerance develops but how many days it takes and how much of the original response survives. Nobody has published that number.
One receptor for the pituitary, a different one for the heart
Hexarelin’s growth hormone effect runs through the growth hormone secretagogue receptor (GHSR), the same receptor ghrelin activates.[4] It also binds a second, unrelated receptor, CD36, identified specifically as a cardiac binding site that appears to mediate its own set of effects on the heart, independent of GHSR.[4]
That is not a footnote. It means Hexarelin’s cardiac activity cannot be explained by growth hormone release at all, which sets it apart from most other GH secretagogues.
One peptide, two receptors that have nothing to do with each other.
The evidence for that second pathway comes entirely from rodents. In a mouse model of induced heart attack, 21 days of daily Hexarelin preserved left ventricular function on MRI and reduced markers of cardiac scarring and inflammation compared with untreated mice.[5] That is a real, three-week, repeated-dosing study, just not in the species anyone asking about “before and after” is thinking of, and no controlled cardiovascular trial in humans has tested whether the same protection holds. The one place Hexarelin has genuine repeated-dosing data behind it is heart tissue in a rodent.
What a stimulation test does besides raise growth hormone
Hexarelin does not raise growth hormone in isolation. In fifteen healthy young men, Korbonits and colleagues found that intravenous Hexarelin significantly increased ACTH and cortisol release, on top of its growth hormone and prolactin effects.[6] That is a broader hormonal signature than a clean growth hormone secretagogue would ideally have.
The same study compared Hexarelin against CRH, the hormone that normally drives the adrenal stress axis, and against desmopressin, a vasopressin analog. From that single session, four things are established:
Cortisol and ACTH rise, to a level comparable to, or slightly below, a maximally stimulating dose of CRH itself.[6]
Prolactin rises alongside growth hormone.[6]
Appetite increases slightly, measured on a validated visual analog scale.[6]
Desmopressin alone does less than either Hexarelin or CRH alone.[6]
In other words, a single Hexarelin injection produces a stress-axis response close to what you would get from injecting the hormone that triggers that axis directly. Reports of facial flushing or injection-site irritation circulate widely in online forums, but no citation surfaced in this search that backs those specific effects for Hexarelin, so they are left out here rather than repeated on faith.
Hexarelin next to MK-677: same goal, different durability
Compare that single-day snapshot to MK-677 (ibutamoren), an oral ghrelin-receptor agonist tested the way Hexarelin never has been. In a two-year, randomized, placebo-controlled trial in 65 healthy older adults, daily MK-677 raised growth hormone and IGF-1 to young-adult levels and increased fat-free mass, with the effect on growth hormone secretion still present at the two-year mark.[7]
Durability was not free. The same trial found that MK-677 also raised fasting glucose and reduced insulin sensitivity over that period.[7] Whatever MK-677’s tradeoffs, going the distance across years of daily dosing is one of the few claims about a growth-hormone secretagogue that has been tested this thoroughly, the way Tesamorelin has been tested for a specific, regulated indication.
Hexarelin has never been run through anything close to that design. The comparison is not close because Hexarelin loses. It is not close because Hexarelin has never entered the race.
What a real before-and-after trial would need
A genuine before-and-after claim for Hexarelin would need a randomized, placebo-controlled trial that dosed people for weeks and measured body composition or physical performance against a control group, the kind of design the 1994 studies never attempted. That trial has not been published. Until it is, “before and after” describes a photography convention borrowed from skincare and fitness marketing, a pattern that shows up across natural and synthetic peptides whenever a compound’s online reputation outruns its trial base.
What has been measured is smaller and considerably less exciting than a transformation: a four-hour hormone spike, a second receptor in heart tissue that nobody has tested in people, and a stress-axis response about as strong as injecting CRH directly.
Bottom line: The only “before and after” Hexarelin has earned in the published literature lasts about four hours per dose. Everything longer term, in humans, is untested.
None of that supports a transformation story. It supports treating Hexarelin as what the data show it to be: a potent, short-acting secretagogue that pharmacologists understood reasonably well for a single afternoon in 1994, and have barely tested since.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Growth hormone-releasing activity of hexarelin in humans. A dose-response study.. European journal of clinical pharmacology, 1994.
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.. The Journal of clinical endocrinology and metabolism, 1994.
Mechanistic diversity involved in the desensitization of G protein-coupled receptors.. Archives of pharmacal research, 2021.
The cardiovascular action of hexarelin.. Journal of geriatric cardiology : JGC, 2014.
Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020.
The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.. The Journal of clinical endocrinology and metabolism, 1999.
Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.. Annals of internal medicine, 2008.
